Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (16617)	3/6/1998 4:14:00 PM
From: Henry Niman	Respond to of 32384

Yes, LGND's small molecule would go directly at the appropriate STAT (I'm not sure if they are targeting STAT 3 or 5, but I think that both are involved in Leptin signalling also, which may be part of the "sticking point" on the leptin signaling alliance. In any event, the LGND small molecule would impact Neupogen (sales of $1/2 Billion?) and Leukine, and since it would be taken orally instead of via injection, the impact could be severe.